All In Biotech

Drug Trial Radar · NCT00957047

Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy

Efficacy and Safety of BIA 2-093 as Adjunctive Therapy for Refractory Partial Seizures in a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Trial

Last checked: Nov 20, 2026Latest source record: Mar 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 395 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

395

Actual

Start

Jul 2004

Primary completion

Aug 2006

Study completion Jan 2008

Sponsor

Lead sponsor
Bial - Portela C S.A.Industry
Sponsor type
Industry
First posted
Aug 12, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to evaluate the efficacy of eslicarbazepine acetate once-daily at doses of 400 mg, 800 mg and 1200 mg compared with placebo as adjunctive therapy in patients with refractory partial epilepsy over a 12-week maintenance period. Patients who complete Part I may enter a 1-year open-label extension.

Conditions

  • Partial Epilepsy

Interventions

  • eslicarbazepine acetateDrug

    oral tablets

  • placeboDrug

    once daily placebo comparator

  • ESL - Part IIDrug

    Eslicarbazepine acetate was supplied as scored 800-mg tablets for daily oral administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PART I - Seizure FrequencyTime frame: 12-week maintenance period
  2. PART II - Nº of Treatment-Emergent Adverse Events (TEAE)Time frame: 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Bial - Portela & Cª, S.A.

    Trofa, Coronado (S.Romão E S. Mamede), Portugal

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.